Prof. Matthew Kiernan

Chief Executive Officer and Institute Director, Neuroscience Research Australia Scientia Professor of Neuroscience at the University of New South Wales, Sydney, Australia Senior Staff Specialist in Neurology, South Eastern Sydney Local Health District

Dementia care is facing immense challenges worldwide, with the growing number of diagnoses and lack of effective therapies. In this video, Professor Matthew Kiernan discusses the complexities of dementia research, including recent insights into neurobiological aetiologies, and promising developments for therapeutics. From targeted monoclonal antibody treatments for specific proteins linked to various forms of dementia, to the critical role of lifestyle and preventative care, Professor Kiernan outlines a multifaceted approach to tackling this global issue.

Related content

Article cover image showing blood samples and a hand description Article
Fluid biomarkers in Alzheimer’s disease: from detecting the pathology to understanding when it causes symptoms

Advances in blood biomarkers are transforming the diagnosis and prognosis of Alzheimer’s disease, helping to assess pathology, disease progression, and co-existing pathologies.

13.10.2026 Alzheimer’s Disease
image Image Diagram showing current and potential applications of blood-based biomarkers across the Alzheimer’s disease pathway
Current and potential applications for fluid biomarkers

Overview of how blood-based biomarkers may support screening, diagnosis, staging, prognosis, and treatment decisions across the Alzheimer’s disease continuum.

13.10.2026 Alzheimer’s Disease
image Image Flowchart illustrating a plasma biomarker testing protocol for symptomatic Alzheimer’s disease
A two-step blood-based algorithm

Overview of a plasma biomarker testing pathway for symptomatic Alzheimer’s disease, using p-tau217 and eMTBR-tau243 to guide diagnostic assessment and identify underlying pathology.

13.10.2026 Alzheimer’s Disease